Identification of DCTN1::ALK Fusion Leads to Initiation of ALK Inhibitor Therapy With Therapeutic Response in a Clinically Challenging Widely Metastatic Malignant Spindle Cell Neoplasm

Abstract

Keywords

malignant spindle cell neoplasm immunohistochemistry next-generation sequencing

Get full access to this article

View all access options for this article.

References

Soda

Choi

Enomoto

, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561-566.

AACR Project GENIE . Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7:818-831.

Cameron

Hitchen

Chandran

, et al. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cochrane Database Syst Rev. 2022;1:Cd013453.

Camidge

Dziadziuszko

Peters

, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the Global Phase III ALEX Study. J Thorac Oncol 2019. 14:1233-1243.

Vidrine

Berry

Garbuzov

Falcon

Tubbs

Bui

. DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS. Childs Nerv Syst. 2021;37:2147-2151.

Dermawan

DiNapoli

Mullaney

, et al. ALK-rearranged mesenchymal neoplasms: a report of 9 cases further expanding the clinicopathologic spectrum of emerging kinase fusion positive group of tumors. Genes Chromosomes Cancer. 2023;62:75-84.

Gao

Zhao

. Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements. Thorac Cancer. 2022;13:1088-1090.

Kemps

Picarsic

Durham

, et al. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood. 2022;139(2):256-280. Blood 2023, 141:2785-2786.